Retiform haemangioendothelioma. 1996

M Fukunaga, and Y Endo, and F Masui, and T Yoshikawa, and E Ishikawa, and S Ushigome
Department of Pathology, Jikei University School of Medicine, Tokyo, Japan.

A case of retiform haemangioendothelioma (RH), a recently described rare cutaneous low-grade angiosarcoma, is presented. A 75-year-old female had a 3.5 cm cutaneous nodule in her right lower thigh with 10 year preoperative duration. Microscopically, the dermis and subcutis contained a diffuse and infiltrative neoplasm which was characterized by long arborizing blood vessels arranged in a retiform pattern lined by cuboidal and flattened cells, occasional hobnail appearance of endothelial cells, and a prominent small lymphocytic infiltrate. Small solid areas were also found. Neither significant cellular atypia nor mitotic activity was observed. Immunohistochemically, the tumour cells reacted with endothelial markers (CD31, CD34, factor-VIII-related antigen) and bound Ulex europaeus agglutinin 1. There was no pericytic component within the tumour. The tumour was diploid by flow cytometry. The patient had a local recurrence 27 months after the excision. These findings support the view that RH is a low-grade angiosarcoma and indicate that RH must be distinguished from conventional angiosarcoma.

UI MeSH Term Description Entries
D007150 Immunohistochemistry Histochemical localization of immunoreactive substances using labeled antibodies as reagents. Immunocytochemistry,Immunogold Techniques,Immunogold-Silver Techniques,Immunohistocytochemistry,Immunolabeling Techniques,Immunogold Technics,Immunogold-Silver Technics,Immunolabeling Technics,Immunogold Silver Technics,Immunogold Silver Techniques,Immunogold Technic,Immunogold Technique,Immunogold-Silver Technic,Immunogold-Silver Technique,Immunolabeling Technic,Immunolabeling Technique,Technic, Immunogold,Technic, Immunogold-Silver,Technic, Immunolabeling,Technics, Immunogold,Technics, Immunogold-Silver,Technics, Immunolabeling,Technique, Immunogold,Technique, Immunogold-Silver,Technique, Immunolabeling,Techniques, Immunogold,Techniques, Immunogold-Silver,Techniques, Immunolabeling
D009364 Neoplasm Recurrence, Local The local recurrence of a neoplasm following treatment. It arises from microscopic cells of the original neoplasm that have escaped therapeutic intervention and later become clinically visible at the original site. Local Neoplasm Recurrence,Local Neoplasm Recurrences,Locoregional Neoplasm Recurrence,Neoplasm Recurrence, Locoregional,Neoplasm Recurrences, Local,Recurrence, Local Neoplasm,Recurrence, Locoregional Neoplasm,Recurrences, Local Neoplasm,Locoregional Neoplasm Recurrences,Neoplasm Recurrences, Locoregional,Recurrences, Locoregional Neoplasm
D004171 Diploidy The chromosomal constitution of cells, in which each type of CHROMOSOME is represented twice. Symbol: 2N or 2X. Diploid,Diploid Cell,Cell, Diploid,Cells, Diploid,Diploid Cells,Diploidies,Diploids
D005260 Female Females
D005434 Flow Cytometry Technique using an instrument system for making, processing, and displaying one or more measurements on individual cells obtained from a cell suspension. Cells are usually stained with one or more fluorescent dyes specific to cell components of interest, e.g., DNA, and fluorescence of each cell is measured as it rapidly transverses the excitation beam (laser or mercury arc lamp). Fluorescence provides a quantitative measure of various biochemical and biophysical properties of the cell, as well as a basis for cell sorting. Other measurable optical parameters include light absorption and light scattering, the latter being applicable to the measurement of cell size, shape, density, granularity, and stain uptake. Cytofluorometry, Flow,Cytometry, Flow,Flow Microfluorimetry,Fluorescence-Activated Cell Sorting,Microfluorometry, Flow,Cell Sorting, Fluorescence-Activated,Cell Sortings, Fluorescence-Activated,Cytofluorometries, Flow,Cytometries, Flow,Flow Cytofluorometries,Flow Cytofluorometry,Flow Cytometries,Flow Microfluorometries,Flow Microfluorometry,Fluorescence Activated Cell Sorting,Fluorescence-Activated Cell Sortings,Microfluorimetry, Flow,Microfluorometries, Flow,Sorting, Fluorescence-Activated Cell,Sortings, Fluorescence-Activated Cell
D006390 Hemangioendothelioma A neoplasm derived from blood vessels, characterized by numerous prominent endothelial cells that occur singly, in aggregates, and as the lining of congeries of vascular tubes or channels. Hemangioendotheliomas are relatively rare and are of intermediate malignancy (between benign hemangiomas and conventional angiosarcomas). They affect men and women about equally and rarely develop in childhood. (From Stedman, 25th ed; Holland et al., Cancer Medicine, 3d ed, p1866) Endothelioma, Vascular,Hemangio-Endothelioma,Endotheliomas, Vascular,Hemangio Endothelioma,Hemangio-Endotheliomas,Hemangioendotheliomas,Vascular Endothelioma,Vascular Endotheliomas
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly
D014841 von Willebrand Factor A high-molecular-weight plasma protein, produced by endothelial cells and megakaryocytes, that is part of the factor VIII/von Willebrand factor complex. The von Willebrand factor has receptors for collagen, platelets, and ristocetin activity as well as the immunologically distinct antigenic determinants. It functions in adhesion of platelets to collagen and hemostatic plug formation. The prolonged bleeding time in VON WILLEBRAND DISEASES is due to the deficiency of this factor. Factor VIII-Related Antigen,Factor VIIIR-Ag,Factor VIIIR-RCo,Plasma Factor VIII Complex,Ristocetin Cofactor,Ristocetin-Willebrand Factor,von Willebrand Protein,Factor VIII Related Antigen,Factor VIIIR Ag,Factor VIIIR RCo,Ristocetin Willebrand Factor
D015214 Antigens, Differentiation, Myelomonocytic Surface antigens expressed on myeloid cells of the granulocyte-monocyte-histiocyte series during differentiation. Analysis of their reactivity in normal and malignant myelomonocytic cells is useful in identifying and classifying human leukemias and lymphomas. Differentiation Antigens, Myelomonocytic,Myelomonocytic Differentiation Antigens,Antigens, Myelomonocytic, Differentiation,Antigens, Myelomonocytic Differentiation

Related Publications

M Fukunaga, and Y Endo, and F Masui, and T Yoshikawa, and E Ishikawa, and S Ushigome
December 2009, Annales de pathologie,
M Fukunaga, and Y Endo, and F Masui, and T Yoshikawa, and E Ishikawa, and S Ushigome
February 2012, The Journal of laryngology and otology,
M Fukunaga, and Y Endo, and F Masui, and T Yoshikawa, and E Ishikawa, and S Ushigome
February 2013, Journal of comparative pathology,
M Fukunaga, and Y Endo, and F Masui, and T Yoshikawa, and E Ishikawa, and S Ushigome
March 2020, World journal of clinical cases,
M Fukunaga, and Y Endo, and F Masui, and T Yoshikawa, and E Ishikawa, and S Ushigome
February 1947, Klinische Medizin; osterreichische Zeitschrift fur wissenschaftliche und praktische Medizin,
M Fukunaga, and Y Endo, and F Masui, and T Yoshikawa, and E Ishikawa, and S Ushigome
March 1997, Annales de pathologie,
M Fukunaga, and Y Endo, and F Masui, and T Yoshikawa, and E Ishikawa, and S Ushigome
May 2000, International journal of dermatology,
M Fukunaga, and Y Endo, and F Masui, and T Yoshikawa, and E Ishikawa, and S Ushigome
June 2003, Archives of dermatology,
M Fukunaga, and Y Endo, and F Masui, and T Yoshikawa, and E Ishikawa, and S Ushigome
November 1989, Histopathology,
M Fukunaga, and Y Endo, and F Masui, and T Yoshikawa, and E Ishikawa, and S Ushigome
April 1997, Histopathology,
Copied contents to your clipboard!